Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New once-a-month injectable contraceptives, with particular reference to Cyclofem/Cyclo-Provera

P E Hall1

  • 1UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland.

International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics
|November 7, 1998
PubMed
Summary

New once-a-month injectable contraceptives combining progestogen and estrogen offer improved bleeding patterns and high efficacy. These hormonal contraceptives provide a safe and effective alternative with minimal side effects for women.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

The introduction of Cyclofem into national family planning programmes: experience from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia. Task Force on Research on Introduction and Transfer of Technologies for Fertility Regulation, Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland.

Contraception·1994
Same author

A review of "once-a-month" combined injectable contraceptives.

Journal of obstetrics and gynaecology·1994
Same author

Transformation of Acetobacter xylinum with plasmid DNA by electroporation.

Plasmid·1992
Same author

Lipid and biochemical changes after low-dose oral contraception.

Contraception·1992
Same author

Progesterone-releasing vaginal rings for use in postpartum contraception. I. In vitro release rates of progesterone from core-loaded rings.

Contraception·1992

Area of Science:

  • Contraception
  • Reproductive Health
  • Endocrinology

Background:

  • Progestogen-only injectable contraceptives are widely used but can disrupt vaginal bleeding patterns.
  • Development of combined injectable contraceptives aims to improve cycle control and user satisfaction.

Purpose of the Study:

  • To evaluate the efficacy and safety of once-a-month injectable contraceptives containing progestogen and estrogen.
  • To compare bleeding patterns and side effects with progestogen-only injectables.
  • To assess pharmacokinetic properties and return to fertility.

Main Methods:

  • Phase III clinical trials were conducted for Mesigyna (norethisterone enanthate/estradiol valerate) and Cyclofem (medroxyprogesterone acetate/estradiol cypionate).
  • Pharmacokinetic studies investigated optimal dosages and ratios of progestogens and estrogens.

Related Experiment Videos

  • Introductory trials of MPA/E2C involved 12,000 women with 100,000 woman-months of experience.

    • Main Results:

    • Annual pregnancy rates were <0.4% for Mesigyna and <0.2% for Cyclofem (MPA/E2C).
    • Over two-thirds of women experienced predictable, regular cycles.
    • Discontinuation due to bleeding problems was less frequent than with progestogen-only injectables.
    • Return to fertility with MPA/E2C was similar to other hormonal or intrauterine methods.
    • Both products had minimal effects on lipids and hemostasis.
    • Introductory trials confirmed high efficacy of MPA/E2C in routine use.

    Conclusions:

    • Once-a-month injectable contraceptives with progestogen and estrogen are safe and effective options.
    • These formulations offer improved bleeding control and fewer side effects compared to progestogen-only injectables.
    • They provide a valuable alternative for women seeking injectable contraception with predictable cycles.